default provider image
ucsf logo

Michael D. Rosenblum, MD, PhD

Dermatology
default provider image
default provider image
ucsf logo

Michael D. Rosenblum, MD, PhD

Dermatology

On this page

About me

Dr. Michael Rosenblum is a dermatologist who specializes in caring for patients with inflammatory and autoimmune skin diseases.

One of the world's leading skin immunologists, Rosenblum's research has led to a better understanding of how immune responses are regulated in tissues. He also studies how to use this knowledge to develop better treatments for autoimmune disorders.

After completing a doctorate in immunology at the Medical College of Wisconsin, Rosenblum earned his medical degree from the same institution. He completed a residency in dermatology at UCSF.

Rosenblum is a member of the American Association of Immunologists, Society for Investigative Dermatology, American Academy of Dermatology and Federation of Clinical Immunology Societies. He has co-founded multiple biotech companies that are developing new treatments for autoimmune diseases.

Education

Board Certification

  • Dermatology, American Board of Dermatology

Residency

  • Dermatology, UCSF Medical Center - OMAG

Internship

  • Transitional, Mercy Hospital Aurora

School

  • MD, Medical College of Wisconsin

Academic Title

  • Professor-in-Residence

Care Keywords

  • Services
    • Dermatology

Provider Research Listing

Browse clinical trials and publications by this provider

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.